http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019166430-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7fb9885b61a0584fb8661e99b528b1ae |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b90b92ecafe55d034280e236df3cd545 |
| publicationDate | 2019-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019166430-A1 |
| titleOfInvention | Estriol component for use in the treatment of er-positive cancers |
| abstract | The present invention relates to the use of an estriol component in the treatment of estrogen receptor positive (ER-positive) cancer in a non-pregnant female human patient, said estriol component being selected from estriol, prodrugs of estriol and combinations thereof, and the treatment comprising uninterrupted, at least once dailyoral administration of doses of the estriol component during a period of at least 4 weeks, wherein the doses are orally administered in dosages equivalent to a daily oral dosage of 0.01 to 2 mg estriol. It was surprisingly found that oral administration of estriol at low dosages can significantly reduce growth of estrogen receptor positive (ER-positive) cancer cells by inducing apoptosis. |
| priorityDate | 2018-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.